Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 4/20 | 0.41 |
| ▸ | HTR1A | P08908 | 3/20 | 0.41 |
| ▸ | VCP | P55072 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL45170 | 0.94 | HSD17B10 (0.41) | HSD17B10DRD4HTR1AVCPMAPT | |
| SCHEMBL45444 | 0.90 | HSD17B10 (0.42) | HSD17B10DRD4HTR1AMAPTPOLB | |
| SCHEMBL45445 | 0.84 | HSD17B10 (0.42) | HSD17B10DRD4HTR1AMAPTPOLB | |
| SCHEMBL42389 | 0.83 | HDAC4 (0.36) | HSD17B10DRD4HTR1AVCPMAPT | |
| SCHEMBL41668 | 0.81 | HDAC4 (0.46) | HSD17B10KDM4EALDH1A1 | |
| SCHEMBL45313 | 0.77 | PRKD1 (0.40) | HSD17B10HTR1AMAPTLMNAKDM4E | |
| SCHEMBL45394 | 0.77 | PRKD1 (0.40) | HSD17B10HTR1AMAPT | |
| SCHEMBL15752123 | 0.76 | BCL3 (0.38) | POLBALDH1A1HTT | |
| SCHEMBL11025237 | 0.75 | F11 (0.44) | HSD17B10KDM4EALDH1A1 | |
| SCHEMBL11029499 | 0.75 | F10 (0.45) | MAPTLMNAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588458-B1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-06-04 | — | — | EP | claimed |
| EP-2588458-B1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-06-04 | — | — | EP | disclosed |
| US-8592594-B2 | Tetrahydro-quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-11-26 | — | — | US | disclosed |
| EP-2588458-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-08 | — | — | EP | disclosed |
| US-20120004218-A1 | NOVEL TETRAHYDRO-QUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-01-05 | — | — | US | disclosed |
| WO-2012001020-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004218-A1 | NOVEL TETRAHYDRO-QUINOLINE DERIVATIVES | GPR119, PRKAB1, PRKAG1 | HSD17B10 375/4885DRD4 3388/4885HTR1A 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.